Robyn T Cohen1, Mark Rodeghier2, Fenella J Kirkham3, Carol L Rosen4, Jane Kirkby5, Michael R DeBaun6, Robert C Strunk7. 1. Department of Pediatrics, Boston University School of Medicine, Boston, Mass. Electronic address: robyn.cohen@bmc.org. 2. Rodeghier Consultants, Chicago, Ill. 3. Neurosciences Unit, University College London, Institute of Child Health, London, United Kingdom. 4. Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio. 5. Portex Respiratory Unit, University College London, Institute of Child Health, London, United Kingdom. 6. Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tenn. 7. Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, Mo.
Abstract
BACKGROUND: The significance of fractional exhaled nitric oxide (Feno) levels in children with sickle cell anemia (SCA) is unclear, but increased levels can be associated with features of asthma and thus increased morbidity. OBJECTIVES: We sought to determine factors associated with Feno and whether Feno levels are associated with increased rates of acute chest syndrome (ACS) and pain. METHODS: All participants had SCA, were part of the prospective observational Sleep and Asthma Cohort study, and had the following assessments: Feno levels, spirometry, blood samples analyzed for hemoglobin, white blood cell counts, eosinophil counts and total serum IgE levels, questionnaires about child medical and family history, and review of medical records. RESULTS: The analytic sample included 131 children with SCA (median age, 11.2 years; age range, 6-18 years) followed for a mean of 16.2 years, including a mean of 5.1 years after baseline Feno data measurements. In multivariable analyses higher Feno levels were associated with ln(IgE) levels (P < .001) and the highest quartile of peripheral eosinophil counts (P = .03) but not wheezing symptoms, baseline spirometric indices, or response to bronchodilator. Multivariable analyses identified that the incident rate of ACS was associated with ln(Feno) levels (P = .03), as well as male sex (P = .025), wheezing causing shortness of breath (P = .002), and ACS at less than 4 years of age (P < .001). Feno levels were not associated with future pain episodes. CONCLUSIONS: Steady-state Feno levels were not associated with an asthma diagnosis, wheezing symptoms, lung function measures, or prior sickle cell morbidity but were associated with markers of atopy and increased risk of future ACS events.
BACKGROUND: The significance of fractional exhaled nitric oxide (Feno) levels in children with sickle cell anemia (SCA) is unclear, but increased levels can be associated with features of asthma and thus increased morbidity. OBJECTIVES: We sought to determine factors associated with Feno and whether Feno levels are associated with increased rates of acute chest syndrome (ACS) and pain. METHODS: All participants had SCA, were part of the prospective observational Sleep and Asthma Cohort study, and had the following assessments: Feno levels, spirometry, blood samples analyzed for hemoglobin, white blood cell counts, eosinophil counts and total serum IgE levels, questionnaires about child medical and family history, and review of medical records. RESULTS: The analytic sample included 131 children with SCA (median age, 11.2 years; age range, 6-18 years) followed for a mean of 16.2 years, including a mean of 5.1 years after baseline Feno data measurements. In multivariable analyses higher Feno levels were associated with ln(IgE) levels (P < .001) and the highest quartile of peripheral eosinophil counts (P = .03) but not wheezing symptoms, baseline spirometric indices, or response to bronchodilator. Multivariable analyses identified that the incident rate of ACS was associated with ln(Feno) levels (P = .03), as well as male sex (P = .025), wheezing causing shortness of breath (P = .002), and ACS at less than 4 years of age (P < .001). Feno levels were not associated with future pain episodes. CONCLUSIONS: Steady-state Feno levels were not associated with an asthma diagnosis, wheezing symptoms, lung function measures, or prior sickle cell morbidity but were associated with markers of atopy and increased risk of future ACS events.
Authors: Joshua J Field; Janet Stocks; Fenella J Kirkham; Carol L Rosen; Dennis J Dietzen; Trisha Semon; Jane Kirkby; Pamela Bates; Sinziana Seicean; Michael R DeBaun; Susan Redline; Robert C Strunk Journal: Chest Date: 2010-08-19 Impact factor: 9.410
Authors: K J Sullivan; N Kissoon; L J Duckworth; E Sandler; B Freeman; E Bayne; J E Sylvester; J J Lima Journal: Am J Respir Crit Care Med Date: 2001-12-15 Impact factor: 21.405
Authors: Robyn T Cohen; Anusha Madadi; Morey A Blinder; Michael R DeBaun; Robert C Strunk; Joshua J Field Journal: Am J Hematol Date: 2011-08-02 Impact factor: 10.047
Authors: Ping An; Emily A Barron-Casella; Robert C Strunk; Robert G Hamilton; James F Casella; Michael R DeBaun Journal: J Allergy Clin Immunol Date: 2011-03-09 Impact factor: 10.793
Authors: Peter J Barnes; Raed A Dweik; Arthur F Gelb; Peter G Gibson; Steven C George; Hartmut Grasemann; Ian D Pavord; Felix Ratjen; Philip E Silkoff; D Robin Taylor; Noe Zamel Journal: Chest Date: 2010-09 Impact factor: 9.410
Authors: Michael R DeBaun; Mark Rodeghier; Robyn Cohen; Fenella J Kirkham; Carol L Rosen; Irene Roberts; Ben Cooper; Janet Stocks; Olu Wilkey; Baba Inusa; John O Warner; Robert C Strunk Journal: Am J Hematol Date: 2014-08-27 Impact factor: 10.047
Authors: Jason E Knuffman; Christine A Sorkness; Robert F Lemanske; David T Mauger; Susan J Boehmer; Fernando D Martinez; Leonard B Bacharier; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2009-01-03 Impact factor: 10.793
Authors: Robert C Strunk; Stanley J Szefler; Brenda R Phillips; Robert S Zeiger; Vernon M Chinchilli; Gary Larsen; Kevin Hodgdon; Wayne Morgan; Christine A Sorkness; Robert F Lemanske Journal: J Allergy Clin Immunol Date: 2003-11 Impact factor: 10.793
Authors: Robert C Strunk; Robyn T Cohen; Benjamin P Cooper; Mark Rodeghier; Fenella J Kirkham; John O Warner; Janet Stocks; Jane Kirkby; Irene Roberts; Carol L Rosen; Daniel I Craven; Michael R DeBaun Journal: J Pediatr Date: 2013-12-31 Impact factor: 4.406
Authors: Jeffrey Glassberg; Caterina Minnitti; Caroline Cromwell; Lawrence Cytryn; Thomas Kraus; Gwen S Skloot; Jason T Connor; Adeeb H Rahman; William J Meurer Journal: Am J Hematol Date: 2017-06-05 Impact factor: 10.047
Authors: Pierachille Santus; Maurizio Rizzi; Dejan Radovanovic; Andrea Airoldi; Andrea Cristiano; Rosalynn Conic; Stephen Petrou; Paolo Daniele Maria Pigatto; Nicola Bragazzi; Delia Colombo; Mohamad Goldust; Giovanni Damiani Journal: Biomed Res Int Date: 2018-09-23 Impact factor: 3.411